174 related articles for article (PubMed ID: 31043821)
41. Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs.
Evans WK; Nefsky M; Pater J; Browman G; Cowan DH
Chronic Dis Can; 2002; 23(4):152-6. PubMed ID: 12517323
[TBL] [Abstract][Full Text] [Related]
42. Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology.
Dankó D; Blay JY; Garrison LP
Health Policy; 2019 Dec; 123(12):1230-1236. PubMed ID: 31337514
[TBL] [Abstract][Full Text] [Related]
43. The reality of economics for oncologists.
Taylor D
Breast; 2017 Jun; 33():183-190. PubMed ID: 28432979
[TBL] [Abstract][Full Text] [Related]
44. Mapping the European cancer research landscape: An evidence base for national and Pan-European research and funding.
Begum M; Lewison G; Lawler M; Sullivan R
Eur J Cancer; 2018 Sep; 100():75-84. PubMed ID: 30014883
[TBL] [Abstract][Full Text] [Related]
45. Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs.
Costa S; Bentley C; Regier DA; McTaggart-Cowan H; Mitton C; Burgess MM; Peacock SJ
BMC Public Health; 2019 Jul; 19(1):977. PubMed ID: 31331312
[TBL] [Abstract][Full Text] [Related]
46. Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study.
Lexchin J
PLoS One; 2019; 14(2):e0212399. PubMed ID: 30768629
[TBL] [Abstract][Full Text] [Related]
47. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
Niraula S; Nugent Z
J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
[No Abstract] [Full Text] [Related]
48. Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology.
Knox KS; Adams JR; Djulbegovic B; Stinson TJ; Tomor C; Bennet CL
Ann Oncol; 2000 Dec; 11(12):1591-5. PubMed ID: 11205468
[TBL] [Abstract][Full Text] [Related]
49. Impact of rarity on Canadian oncology health technology assessment and funding.
Keech J; Dai WF; Trudeau M; Mercer RE; Naipaul R; Wright FC; Ferguson SE; Darling G; Gavura S; Eisen A; Kouroukis CT; Beca J; Chan KKW
Int J Technol Assess Health Care; 2020 Aug; ():1-6. PubMed ID: 32779560
[TBL] [Abstract][Full Text] [Related]
50. Risk management frameworks for human health and environmental risks.
Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
[TBL] [Abstract][Full Text] [Related]
51. Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example.
McDonald H; Charles C; Elit L; Gafni A
J Mark Access Health Policy; 2016; 4():. PubMed ID: 27489586
[TBL] [Abstract][Full Text] [Related]
52. Not All Canadian Cancer Patients Are Equal-Disparities in Public Cancer Drug Funding across Canada.
MacPhail C; Snow S
Curr Oncol; 2022 Mar; 29(3):2064-2072. PubMed ID: 35323366
[TBL] [Abstract][Full Text] [Related]
53. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report.
Fry RN; Avey SG; Sullivan SD
Value Health; 2003; 6(5):505-21. PubMed ID: 14627057
[TBL] [Abstract][Full Text] [Related]
54. Health technology assessment in Australia: a role for clinical registries?
Scott AM
Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
[TBL] [Abstract][Full Text] [Related]
55. Using a public hospital funding model to strengthen a case for improved nutritional care in a cancer setting.
Boltong AG; Loeliger JM; Steer BL
Aust Health Rev; 2013 Jun; 37(3):286-90. PubMed ID: 23731960
[TBL] [Abstract][Full Text] [Related]
56. Determinants of the Cancer Drug Funding Process in Canada.
Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P
Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362
[TBL] [Abstract][Full Text] [Related]
57. Evaluating an oncology systemic therapy computerized physician order entry system using international guidelines.
Gandhi S; Tyono I; Pasetka M; Trudeau M
J Oncol Pract; 2014 Mar; 10(2):e14-25. PubMed ID: 24254406
[TBL] [Abstract][Full Text] [Related]
58. [Benefit-risk evaluation of new drugs as a basis for decisions on prioritization in hematology/oncology: methodical challenges and problem-solving strategies].
Ludwig WD; Schildmann J
Onkologie; 2011; 34 Suppl 1():6-10. PubMed ID: 21389762
[TBL] [Abstract][Full Text] [Related]
59. Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands.
Franken MG; van Gils CW; Gaultney JG; Delwel GO; Goettsch W; Huijgens PC; Steenhoek A; Punt CJ; Koopman M; Redekop WK; Uyl-de Groot CA
Eur J Cancer; 2013 Jan; 49(1):8-16. PubMed ID: 22809557
[TBL] [Abstract][Full Text] [Related]
60. Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR.
Richter T; Janoudi G; Amegatse W; Nester-Parr S
Orphanet J Rare Dis; 2018 Feb; 13(1):15. PubMed ID: 29386040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
